SCHEMBL20134974

SCHEMBL20134974

CCCC(=O)c1ccc(C)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HPGD P15428 5/20 0.46
ALDH1A1 P00352 3/20 0.46
TSHR P16473 3/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.41
ACKR3 P25106 1/20 0.40
MAPT P10636 5/20 0.40
RAB9A P51151 5/20 0.40
LMNA P02545 2/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
NPC1 O15118 4/20 0.39
NPSR1 Q6W5P4 3/20 0.39
HTT P42858 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688370 1.00 MEN1 (0.49) MEN1KMT2AHPGDALDH1A1TSHR
SCHEMBL24427040 0.86 MEN1 (0.49) MEN1KMT2AHPGDTSHRHSD17B10
SCHEMBL30494600 0.85 HSP90AB1 (0.47) MEN1KMT2AHPGDALDH1A1TSHR
SCHEMBL9720605 0.85 HSP90AB1 (0.47) MEN1KMT2AHPGDALDH1A1TSHR
SCHEMBL14053155 0.84 KMT2A (0.70) MEN1KMT2AHPGDALDH1A1TSHR
SCHEMBL6944180 0.84 CES2 (0.57) HPGDALDH1A1TSHRHSD17B10ALOX15
SCHEMBL176969 0.82 HTT (0.54) MEN1KMT2AHPGDALDH1A1TSHR
SCHEMBL5569924 0.81 MEN1 (0.51) MEN1KMT2AHPGDALDH1A1TSHR
SCHEMBL5568822 0.81 MEN1 (0.71) MEN1KMT2AHPGDALDH1A1TSHR
SCHEMBL6632953 0.81 MEN1 (0.43) MEN1KMT2AHPGDTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MEN1 3735/4885KMT2A 2568/4885HPGD 74/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MEN1 2913/4885KMT2A 2539/4885HPGD 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.